Gilead, LEO Pharma
Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma
Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than before, into inflammation, penning a major $1.7 billion deal with dermatology specialist Leo Pharma on the eve of the J.P. Morgan Healthcare conference.
Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to ...
Harbor Capital Advisors Inc. grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.3% during the 4th ...
Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...
Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...
ST Germain D J Co. Inc. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 15.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange ...
After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...
Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...
The Marion Star on MSN15h
Cardington pulls away late in its rivalry game with Mount Gilead Saturday afternoonCardington overcomes Mount Gilead's second-half rally in a Knox Morrow Athletic Conference boys basketball game.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback